Antiangiogenic therapies in breast cancer

Roberta Sarmiento, Mario Rosario D'Andrea, Francesca Cacciamani, Francesca Salerno, Giampietro Gasparini

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a complex, multistep process that is involved in the progression and prognosis of several types of cancer. In particular, it has been demonstrated that angiogenesis plays a central role in the progression of breast cancer. This review evaluates results from clinical trials in which the efficacy of conventional chemotherapeutic agents was compared with that of novel antiangiogenic compounds for the treatment of breast cancer, and provides a summary of trials that were ongoing at the time of publication in the neoadjuvant and adjuvant settings.

Original languageEnglish
Pages (from-to)1334-1345
Number of pages12
JournalCurrent Opinion in Investigational Drugs
Volume10
Issue number12
Publication statusPublished - Dec 2009

Keywords

  • Angiogenesis
  • Bevacizumab
  • Breast cancer
  • Tyrosine kinase inhibitor
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Antiangiogenic therapies in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Sarmiento, R., D'Andrea, M. R., Cacciamani, F., Salerno, F., & Gasparini, G. (2009). Antiangiogenic therapies in breast cancer. Current Opinion in Investigational Drugs, 10(12), 1334-1345.